DEBIOPHARM AND TCLAND SIGN R&D AND EXCLUSIVE LICENSE OPTION

A A

The Debiopharm Group, an independent global drug development company specialising in oncology and serious medical conditions, and TcLand S.A., a French biopharmaceutical company specialising in the development of immunological biomarkers and therapeutic molecules to control organ transplant rejection and immune disorders, announced the signature of an exclusive in-licensing option agreement for the development of the fusion protein sc28AT, a CD28 antagonist in preclinical development.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/05-22-2006/0004366140&EDATE=)